Formulation to treat or prevent parasitic infection

Details Formulation to treat or prevent parasitic infection Formulation to treat or prevent parasitic infection

2006-02-14

2006-02-14

Price, Elvis O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S025000, C514S023000, C536S004100, C536S055100, C536S018700, C536S123100

Reexamination Certificate

active

06998392

ABSTRACT:
The invention provides a formulation for treatment or prevention of a parasitic infection such as a protozoan or helminths infection, for example:Giardia. The formulation comprises at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, GD1b, NANA, and sialic acid. The formulation may be used to supplement foods or liquids, for example: infant formula, baby food, baby cereal, juice, dehydrated camping food, or bottled water.

REFERENCES:
patent: 4762822 (1988-08-01), Ettinger
Isasi et al. (Acta Tropica (1999), 73(3), 295-302) (Absract Sent).
Sigma Chemical Company Catalog (Biochemicals Organic Compounds for Research and Diagnostic Reagents), 1993 edition (Abstract Sent).
Belosevic and Faubert,“Giardi muris: Correclation between Oral Dosage, Course of Infection, and Trophozoite Distribution in the Mouse Small Intestine”, 1983, Exp. Parasitol., 56:93-100.
Bouhours and Bouhours, “Developmental Changes of Hematoside of Rat Small Intestine”, 1983, J. Biol. Chem., 258:299-304.
Brown and Rose, “Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains during Transport to the Apical Cell Surface”, 1992, Cell, 68:533-544.
Buret et al., “Growth, activites of enzymes in the small intestine, and ultrastructure of microvillous border in gerbils infected withGiardia duodenalis”, 1991, Parasitol Res., 77:109-114.
Clandinin and Yamashiro, “Dietary Factors Affecting the Incidence of Dietary Fat-Induced Myocardial Lesions”, 1982, J. Nutr., 112: 825-828.
Daniels And Belosevic, “Disaccharidase activity in male and female C57BL/6 mice infected withGiardia muris”, 1995, Parasitol Res., 81 : 143-147.
Diamond et al., “A new medium for the axenic cultivation ofEntamoeba histolyticaand otherEntamoeba”, 1978, Trans. R. Soc. Trop. Med. Hyg., 72:431-432.
Farthing, “Giardiasis”, 1996, Gastro. Clin. North Am., 25:493-515.
Folch And Sloane-Stanley, “A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues”, 1957, J. Biol. Chem., 226:497-509.
Forstner and Wherrett, “Plasma Membrane and Mucosal Glycosphingolipids in the Rat Intestine”, 1973, Biochim. Biophys. Acta., 306:446-459.
Gibson et al.,“Giardia lamblia: Incorporation of Free and Conjugated Fatty Acids into Glycerol-Based Phospholipids”, 1999, Exp. Parasitol., 92:1-11.
Gillin,“Giardia lambia: The Role of Conjugated and Unconjugated Bile Salts in Killing by Human Milk”. 1987, Exp. Parasitol., 63:74-83.
Gillin et al., “Cholate-Dependent Killing ofGiardia lambliaby Human Milk”, 1985, Infect. Immun., 47:619-622.
Gillon et al., “Features of small intestinal pathology (epithelial cell kinetics, intraepithelial lymphocytes, disaccharidases) in a primary Giardia muris infection”, 1982, Gut., 23:498-506.
Holmgren et al., “Comparison of Receptors for Cholera andEscherichia coliEnterotoxins in Human Intestine”, 1985, Gasteroenterology, 89:27-35.
Iwamori et al., “Gangliosides of Various Rat Tissues: Distribution of Ganglio-N-Tetraose-Containing Gangliosides and Tissue-Characteristic Composition of Gangliosides”, 1984, J. Biochem., 95:761-770.
Jarroll et al., “Lipid and Carbohydrate Metabolism ofGiardia lamblia”, 1981, Mol. Biochem. Parasitol., 2:187-196.
Jennnings et al., “The Significance of Lowered Jejunal Disaccharidase Levels”, 1976, Aust. NZ J. Med. 6:556-560.
Karlsson, “Microbial recognition of target-cell glycoconjugates”, 1995, Curr. Opin. Structur. Bio., 5:622-635.
Kyogashima et al., “Escherichia coliK99 Binds toN-Glycolylsialoparagloboside andN-Glycolyl-GM3 Found in Piglet Small Intestine”, 1989, Arch. Biochem. Biophys., 270:391-397.
Laegreid and Otnaess, “Trace Amounts of Ganglioside GM1 in Human Milk Inhibit Enterotoxins fromVibrio CholeraeandEscherichia Coli”, 1987, Life Sci., 40:55-62.
Ortega-Barria et al., “Growth Inhibition of the Intestinal ParasiteGiardia lambliaby a Dietary Lectin Is Associated with Arrest of the Cell Cycle”, 1994, J. Exp. Med., 94:2283-2288.
Reiner et al., “Human Milk KillsGiardia lambliaby Generating Toxic Lipolytic Products”, 1986, J. Infect. Dis., 154:825-832.
Roberts-Thomson et al., “Giardiasis in the Mouse: an Animal Model”, 1976, Gastroenterology, 71:57-61.
Rohrer et al., “Killing ofGiardia lambliaby Human Milk Is Mediated by Unsaturated Fatty Acids”, 1986, Antimicrob. Agents Chemother., 30:254-257.
Rolsma et al., “Structure and Function of a Ganglioside Receptor for Porcine Rotavirus”, 1998, J. Virol., 72:9079-9091.
Rueda et al., “Changes during Lactation in Ganglioside Distribution in Human Milk from Mothers Delivering Preterm and Term Infants”, 1996, Biol. Chem., 377:599-601.
Rueda et al., “Addition of gangliosides to an adapted milk formula modifies levels of fecalEscherichia coliin preterm newborn infants”, 1998, J. Pediatr., 133:90-94
Sorice et al., “Evidence for the existence of ganglioside molecules in the antigen ofEntamoeba histolytica”, 1996, Parasite Immunol., 18:133-137.
Stevens et al., “Uptake and Cellular Localization of Exogenous Lipids byGiardia lamblia, a Primitive Eukaryote”, 1997, Exp. Parasitol., 86:133-143.
Underdown et al., “Giardiasis in Mice: Studies on the Characteristics of Chronic Infection in C3H/He MICE”, 1981, J. Immunol., 126:669-672.
Vazquez et al., “Dietary gangliosides positively modulate the percentages of Th1 and Th2 lymphocyte subsets in small intestine of mice at weaning”, 2001, BioFactors, 15:1-9.
Walterspiel et al., “Secretory Anti-Giardia lambliaAntibodies in Human Milk: Protective Effect Against Diarrhea”, 1994, Pediatrics, 93:28-31.
Watarai et al., “Gangliosides as a Possible Receptor on the Bovine Erythrocytes forTheileria sergenti”, 1995, J. Vet. Med. Sci., 57:17-22.
Williams et al., “The Use of Sep-Pak™ C18Cartridges During the Isolation of Gangliosides”, 1980, J. Neurochem., 35:266-269.
Wolfe, 1992, Clin. Microbiol. Rev., 5:93-100.

Affiliated with

Also associated with

Rating

Formulation to treat or prevent parasitic infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation to treat or prevent parasitic infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation to treat or prevent parasitic infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3657560